Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells - PubMed (original) (raw)
Clinical Trial
. 2000 Nov 1;96(9):3102-8.
Affiliations
- PMID: 11049990
Free article
Clinical Trial
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
P Brossart et al. Blood. 2000.
Free article
Abstract
Vaccination of patients with cancer using dendritic cells (DCs) was shown to be effective for B-cell lymphoma and malignant melanoma. Here we provide evidence that patients with advanced breast and ovarian cancer can be efficiently vaccinated with autologous DCs pulsed with HER-2/neu- or MUC1-derived peptides. Ten patients were included in this pilot study. The DC vaccinations were well tolerated with no side effects. In 5 of 10 patients, peptide-specific cytotoxic T lymphocytes (CTLs) could be detected in the peripheral blood using both intracellular IFN-gamma staining and (51)Cr-release assays. The major CTL response in vivo was induced with the HER-2/neu-derived E75 and the MUC1-derived M1.2 peptide, which lasted for more than 6 months, suggesting that these peptides might be immunodominant. In addition, in one patient vaccinated with the MUC1-derived peptides, CEA- and MAGE-3 peptide-specific T-cell responses were detected after several vaccinations. In a second patient immunized with the HER-2/neu peptides, MUC1-specific T lymphocytes were induced after 7 immunizations, suggesting that antigen spreading in vivo might occur after successful immunization with a single tumor antigen. Our results show that vaccination of DCs pulsed with a single tumor antigen may induce immunologic responses in patients with breast and ovarian cancer. This study may be relevant to the design of future clinical trials of other peptide-based vaccines.
Similar articles
- Dendritic cells in vaccination therapies of malignant diseases.
Brossart P. Brossart P. Transfus Apher Sci. 2002 Oct;27(2):183-6. doi: 10.1016/s1473-0502(02)00041-1. Transfus Apher Sci. 2002. PMID: 12350054 Review. - Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE. Mittendorf EA, et al. Cancer. 2006 Jun 1;106(11):2309-17. doi: 10.1002/cncr.21849. Cancer. 2006. PMID: 16596621 Clinical Trial. - The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
Kim DK, Kim JH, Kim YT, Kim JW, Ioannides CG. Kim DK, et al. Yonsei Med J. 2002 Dec;43(6):691-700. doi: 10.3349/ymj.2002.43.6.691. Yonsei Med J. 2002. PMID: 12497651 - Dendritic cell gene therapy.
Onaitis M, Kalady MF, Pruitt S, Tyler DS. Onaitis M, et al. Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review.
Cited by
- Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review.
Dasgupta S, Gayen S, Chakraborty T, Afrose N, Pal R, Mahata S, Nasare V, Roy S. Dasgupta S, et al. Med Oncol. 2024 Mar 27;41(5):98. doi: 10.1007/s12032-024-02337-1. Med Oncol. 2024. PMID: 38536512 Review. - Development of an obesity-related multi-gene prognostic model incorporating clinical characteristics in luminal breast cancer.
Zhang H, Ma S, Wang Y, Chen X, Li Y, Wang M, Xu Y. Zhang H, et al. iScience. 2024 Feb 5;27(3):109133. doi: 10.1016/j.isci.2024.109133. eCollection 2024 Mar 15. iScience. 2024. PMID: 38384850 Free PMC article. - Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.
Lekshmy M, Dhanya CR, Smrithi JS, Sindhurani JA, Vandanamthadathil JJ, Veettil JT, Anila L, Lathakumari VS, Nayar AM, Madhavan M. Lekshmy M, et al. Pharmaceuticals (Basel). 2023 Jul 24;16(7):1054. doi: 10.3390/ph16071054. Pharmaceuticals (Basel). 2023. PMID: 37513965 Free PMC article. Review. - Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A, Ramani V, Bharti V, de Lima Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga C, Richmond A, Reddy SM, Vilgelm A. Kumar A, et al. J Immunother Cancer. 2023 May;11(5):e006019. doi: 10.1136/jitc-2022-006019. J Immunother Cancer. 2023. PMID: 37230537 Free PMC article. - Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, Ibrahim JG, Bixby L, Reisdorf S, Laurie SJ, Park YA, Anders CK, Collichio FA, Muss HB, Carey LA, van Deventer HW, Dees EC, Serody JS. Vincent BG, et al. J Immunol. 2023 Jul 15;211(2):219-228. doi: 10.4049/jimmunol.2300077. J Immunol. 2023. PMID: 37204246 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous